Such a high level of expression of CD38 on MM cells suggests that there is an excellent therapeutic window for isatuximab targeting malignant cells via cytotoxic mechanisms, with minimal adverse effects on normal CD38-expressing immune cells anticipated (37). The gene discussed is CD38; the disease is Miyoshi myopathy.